Literature DB >> 22488947

Rituximab-associated colitis.

Mahesh Bhalme, Stephen Hayes, Andrew Norton, Simon Lal, Hector Chinoy, Peter Paine.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22488947     DOI: 10.1002/ibd.22963

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


× No keyword cloud information.
  6 in total

Review 1.  A comprehensive review of rituximab therapy in rheumatoid arthritis patients.

Authors:  Soheil Tavakolpour; Samira Alesaeidi; Mohammad Darvishi; Mojtaba GhasemiAdl; Sahar Darabi-Monadi; Meisam Akhlaghdoust; Somayeh Elikaei Behjati; Arash Jafarieh
Journal:  Clin Rheumatol       Date:  2019-08-01       Impact factor: 2.980

2.  Fulminant Colitis Following Rituximab Therapy.

Authors:  Seth Lipka; Seymour Katz; James M Crawford
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-01

3.  Efficient long-term depletion of CD20+ B cells by rituximab does not affect gut-resident plasma cells.

Authors:  Mathieu Uzzan; Huaibin M Ko; Adam K Rosenstein; Kamron Pourmand; Jean-Frederic Colombel; Saurabh Mehandru
Journal:  Ann N Y Acad Sci       Date:  2017-12-31       Impact factor: 5.691

Review 4.  Inflammatory bowel diseases: Current problems and future tasks.

Authors:  Giovanni C Actis; Rinaldo Pellicano; Floriano Rosina
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-08-06

Review 5.  Gut inflammation induced by drugs: Can pathology help to differentiate from inflammatory bowel disease?

Authors:  Naoimh Herlihy; Roger Feakins
Journal:  United European Gastroenterol J       Date:  2022-05-28       Impact factor: 6.866

Review 6.  Anti-Inflammatory Biologics and Anti-Tumoral Immune Therapies-Associated Colitis: A Focused Review of Literature.

Authors:  Weixun Zhou; Yan Huang; Jinping Lai; Jun Lu; Michael Feely; Xiuli Liu
Journal:  Gastroenterology Res       Date:  2018-05-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.